Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
; 37(6): e368-71, 2015 Aug.
Article
in En
| MEDLINE
| ID: mdl-25929609
ABSTRACT
Imatinib mesylate has dramatically improved the outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph* ALL) and is now included as first-line therapy. Uncommon adverse effects of this drug for pediatric use, however, are largely unknown. We report the first case of a 9-year-old child who developed severe acute hepatitis with grade 4 transaminases and bilirubin elevation during imatinib treatment for Ph* ALL. Liver biopsy showed extensive lobular and pericentral necrosis of hepatocytes. Liver function recovered after discontinuing imatinib with a 4-week prednisolone. Extensive hepatic necrosis should be considered not only in adults but also in children under imatinib administration.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperazines
/
Pyrimidines
/
Benzamides
/
Philadelphia Chromosome
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Hepatitis
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Adult
/
Child
/
Female
/
Humans
Language:
En
Journal:
J Pediatr Hematol Oncol
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2015
Document type:
Article
Affiliation country:
Japan